Ensign Peak Advisors Inc Cuts Stock Position in Morphic Holding, Inc. (NASDAQ:MORF)

Ensign Peak Advisors Inc decreased its holdings in Morphic Holding, Inc. (NASDAQ:MORFGet Rating) by 7.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 351,070 shares of the company’s stock after selling 29,577 shares during the quarter. Ensign Peak Advisors Inc owned 0.95% of Morphic worth $16,634,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Swiss National Bank raised its stake in shares of Morphic by 1.0% in the third quarter. Swiss National Bank now owns 40,000 shares of the company’s stock valued at $2,266,000 after acquiring an additional 400 shares in the last quarter. Rhumbline Advisers increased its holdings in Morphic by 2.4% during the 4th quarter. Rhumbline Advisers now owns 20,800 shares of the company’s stock worth $986,000 after purchasing an additional 480 shares during the period. Credit Suisse AG raised its position in Morphic by 8.8% in the 3rd quarter. Credit Suisse AG now owns 11,949 shares of the company’s stock valued at $677,000 after purchasing an additional 970 shares in the last quarter. Squarepoint Ops LLC boosted its stake in shares of Morphic by 27.1% in the 3rd quarter. Squarepoint Ops LLC now owns 10,315 shares of the company’s stock valued at $584,000 after buying an additional 2,202 shares during the period. Finally, HighVista Strategies LLC grew its position in shares of Morphic by 13.6% during the third quarter. HighVista Strategies LLC now owns 20,345 shares of the company’s stock worth $1,152,000 after buying an additional 2,428 shares in the last quarter. 72.87% of the stock is owned by institutional investors and hedge funds.

In related news, insider Bruce Rogers sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, April 1st. The stock was sold at an average price of $41.03, for a total transaction of $410,300.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 31.40% of the company’s stock.

Shares of NASDAQ:MORF opened at $22.44 on Friday. Morphic Holding, Inc. has a 12 month low of $21.20 and a 12 month high of $68.75. The firm has a market capitalization of $858.78 million, a P/E ratio of -7.79 and a beta of 1.46. The company’s fifty day moving average price is $35.19 and its 200 day moving average price is $42.28.

Morphic (NASDAQ:MORFGet Rating) last released its quarterly earnings results on Wednesday, May 4th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.04). Morphic had a negative return on equity of 31.37% and a negative net margin of 559.19%. Research analysts anticipate that Morphic Holding, Inc. will post -3.46 EPS for the current fiscal year.

A number of brokerages recently issued reports on MORF. BMO Capital Markets decreased their price target on shares of Morphic from $102.00 to $83.00 in a research note on Monday, February 28th. Canaccord Genuity Group initiated coverage on shares of Morphic in a research report on Thursday, March 31st. They set a “buy” rating and a $68.00 price objective for the company. Canaccord Genuity Group initiated coverage on Morphic in a report on Thursday, March 31st. They issued a “buy” rating on the stock. Royal Bank of Canada decreased their price target on Morphic from $82.00 to $76.00 and set an “outperform” rating for the company in a report on Friday, February 25th. Finally, BTIG Research began coverage on Morphic in a report on Friday, February 11th. They issued a “buy” rating and a $64.00 price objective on the stock. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $71.67.

Morphic Profile (Get Rating)

Morphic Holding, Inc, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases.

See Also

Want to see what other hedge funds are holding MORF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Morphic Holding, Inc. (NASDAQ:MORFGet Rating).

Institutional Ownership by Quarter for Morphic (NASDAQ:MORF)

Receive News & Ratings for Morphic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphic and related companies with MarketBeat.com's FREE daily email newsletter.